Adoptiver Transfer von Spender-B-Lymphozyten ist sicher und verbessert die Immunität bei Patienten nach allogener Stammzelltransplantation – eine Phase I/IIa first-in-human Studie
Lambros Kordelas (Essen / DE; Ratingen / DE), Hannes Tittlbach (Erlangen / DE), Andrea Schneider (Erlangen / DE), Ingrid Vasova (Erlangen / DE), Julian Strobel (Erlangen / DE), Susanne Herold (Erlangen / DE), Stefanie Maas (Erlangen / DE), Bernd M. Spriewald (Erlangen / DE), Roland Repp (Kiel / DE), Michael Mach (Erlangen / DE), Daniel Wolff (Regensburg / DE), Matthias Edinger (Erlangen / DE), Andreas Mackensen (Erlangen / DE), Thomas H. Winkler (Erlangen / DE), Julia Winkler (Erlangen / DE)
Immune reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is slow and patients carry a high and prolonged risk for opportunistic infections. We hypothesized that the adoptive transfer of donor B cells can foster post-HSCT immuno-reconstitution. Here we report on the results of a first-in-human phase I/IIa study aimed to evaluate the feasibility and safety of adoptively transferred donor B cells and to test their activity upon recall vaccination.
GMP-grade B cell products were generated from the original stem cell donor donor by leukapheresis. 15 allo-HSCT patients were enrolled and treated after taper of immunosuppression (median day +148, range 130 to 160). Patients with an EBV reactivation > 10.000 copies/ml and an acute GVHD grade III/IV in their history were excluded. Patients received four different doses of B cells (0.5x106 - 4.0x106 B-cells per kg body weight (BW)). To test the activity of infused donor memory B cells in vivo patients were vaccinated with a pentavalent vaccine 7 days after B cell transfer. The primary endpoint was safety and tolerability. The secondary endpoints were frequency of antibody-producing cells between dose groups 7 days after vaccination.
After two step separation (CD3 depletion and CD19 enrichment) the median proportion of B cells was 96.1% (range 84.9-99.1%) and of CD3-positive T cells 0.08% (range 0.01%-0.82%). We observed a significant increase of plasmablasts after vaccination and an increase of serum titers against vaccine antigens with a stronger response in patients receiving higher B cell numbers. The analysis of immunoglobulin VH-sequences by next-generation-sequencing revealed that plasmablasts responding to the vaccination originated from memory B cell clones from the donor. Donor B cell transfer was safe as no EBV reactivation was observed, and only low-grade GvHD occurred in 4 out of 15 patients.
This phase I/IIa first-in-human study on adoptively transferred donor B cells was designed to evaluate safety (EBV reactivation, GVHD) and efficacy in improving humoral immunity after allo-HSCT. Our data show that transfer of donor B cells into allo-HSCT recipients is feasible and safe and resulted in enhanced memory B-cell responses. This pilot trial may pave the way for further studies exploring the adoptive transfer of memory B cells to reduce the frequency of infections after allo-HSCT.
There are no conflict of interests.
Auf unserem Internetauftritt verwenden wir Cookies. Bei Cookies handelt es sich um kleine (Text-)Dateien, die auf Ihrem Endgerät (z.B. Smartphone, Notebook, Tablet, PC) angelegt und gespeichert werden. Einige dieser Cookies sind technisch notwendig um die Webseite zu betreiben, andere Cookies dienen dazu die Funktionalität der Webseite zu erweitern oder zu Marketingzwecken. Abgesehen von den technisch notwendigen Cookies, steht es Ihnen frei Cookies beim Besuch unserer Webseite zuzulassen oder nicht.